Physician profile
Vinod Krishnan
NPI 1518156967
$2,232.35
in general payments reported to CMS, 2019-2025
31 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $229 · 2021: $260 · 2022: $251 · 2023: $394 · 2024: $443 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $380.39 | 2019-2020 | |
| Biogen, INC. | $295.11 | 2019-2025 | Tysabri, Leqembi, Vumerity |
| Abbvie INC. | $160.07 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $154.44 | 2020-2025 | Ongentys 50mg Capsules 30, Crexont |
| Csl Behring | $136.85 | 2022-2024 | Hizentra |
| Alexion Pharmaceuticals, INC. | $120.31 | 2019-2024 | Ultomiris |
| Vanda Pharmaceuticals INC. | $113.44 | 2024 | Ponvory |
| Ucb, INC. | $90.37 | 2019-2024 | Zilbrysq, Fintepla |
| Argenx US, INC. | $83.49 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $76.64 | 2021-2025 | |
| Sk Life Science, INC. | $76.52 | 2022 | |
| Pfizer INC. | $71.03 | 2023-2025 | |
| Lilly USA, LLC | $49.89 | 2020-2025 | Kisunla, Amyvid |
| Amgen INC. | $49.24 | 2020-2021 | |
| Emd Serono, INC. | $43.08 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $29.76 | 2024 | |
| Novartis Pharmaceuticals Corporation | $29.74 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $27.87 | 2021-2023 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $25.42 | 2023 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $24.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.95 | 2021 | |
| Abbott Laboratories | $21.86 | 2024 | Infinity |
| Grifols USA, LLC | $21.78 | 2025 | Gamunex-C |
| Sumitomo Pharma America, INC. | $19.85 | 2024 | Aptiom |
| Neurelis, INC. | $19.38 | 2025 | Valtoco |
| Ipsen Biopharmaceuticals, INC | $18.07 | 2025 | Dysport |
| Kyowa Kirin, INC. | $16.76 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.55 | 2022 | |
| Eisai INC. | $12.98 | 2023 | |
| Allergan, INC. | $12.81 | 2020 | |
| Genentech USA, INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.